| 1995-10 |
Established Medinet Corporation (capital: 10 million yen) in Nish-Shimbashi, Minato-ku, Tokyo, aiming to provide new medical services based on preventive medicine |
| 1995-10 |
Founded in Nishi-Shimbashi, Minato-ku, Tokyo, aiming to provide new medical support business in preventive medicine (capital: JPY10 million). |
| 1999-04 |
Established the Molecular Immunology Research Institute in Setagaya-ku, Tokyo, installed a cell processing facility (Seta CPC) for Seta Clinic, and launched comprehensive immune cell therapy support services |
| 1999-04 |
Established the Institute of Molecular Immunology in Seta, Setagaya-ku, Tokyo, built the Cell Processing Center for Seta Clinic (Seta CPC), and began offering its core business, Immuno-Cell Therapy Total Support Service. |
| 2000-12 |
Relocated headquarters to Shinbashi, Minato-ku, Tokyo |
| 2000-12 |
Relocated its Head Office to Shimbashi, Minato-ku, Tokyo. |
| 2001-08 |
Certified under the |
| 2001-08 |
Approved by the Ministry of Health, Labour and Welfare for the 'Project for development of new business fields' under the Act for Facilitating the Creation of New Business. |
| 2001-08 |
Ministry of Health, Labour and Welfare approved "Project for development of new business fields" under the Act for Facilitating the Creation of New Business. |
| 2001-10 |
Relocated headquarters to Shin-Yokohama, Kohoku Ward, Yokohama City, established a cell processing facility (Shin-Yokohama CPC1) for contracted medical institutions, and launched comprehensive immune cell therapy support services. |
| 2001-10 |
Relocated its Head Office to Shin-Yokohama, Kohoku-ku, Yokohama, constructed Shin-Yokohama CPC1, and started providing Immuno-Cell Therapy Total Support Service to contracted Medical Institutions. |
| 2002-04 |
Established an advanced medical research institute in Kohoku Ward, Yokohama City, Kanagawa Prefecture. |
| 2002-04 |
Established the Institute of Medical Science in Kohoku-ku, Yokohama-shi, Kanagawa. |
| 2002-07 |
Expanded the cell processing facility (Shin-Yokohama CPC2) for contracted medical institutions. |
| 2002-07 |
Established Shin-Yokohama CPC2 for contracted medical institutions. |
| 2003-05 |
Established a research and development center in Tamagawa-dai, Setagaya Ward, Tokyo, transferred the Molecular Immunology Institute and the Advanced Medical Research Institute to the same center, and renamed the Advanced Medical Research Institute to the "Institute of Molecular Genetics." |
| 2003-05 |
Newly established the Research and Development Center at Tamagawadai, Setagaya-ku, Tokyo. Transferred the Institute of Molecular Immunology and the Institute of Medical Science to the new institute, renaming the latter to 'Institute of Molecular Genetics'. |
| 2003-05 |
Established a research and development center in Tamagawa-dai, Setagaya-ku, Tokyo, relocating the Molecular Immunology Research Institute and the Advanced Medical Research Institute within the same center, and renamed the Advanced Medical Research Institute to the "Molecular Genetics Research Institute." |
| 2003-06 |
Opened an Osaka branch in Esaka-cho, Suita City, Osaka Prefecture, installed a cell processing facility (Osaka CPC) for contracted medical institutions, and launched comprehensive immune cell therapy support services. |
| 2003-06 |
Established Osaka Office in Esaka-cho, Suita-shi, Osaka, built Osaka CPC, and began providing Immuno-Cell Therapy Total Support Service to contracted medical institutions. |
| 2003-07 |
Received the 1st 'Courageous Management Award' sponsored by the Tokyo Chamber of Commerce and Industry. |
| 2003-07 |
Received 1st "Courageous Management Award" sponsored by the Tokyo Chamber of Commerce and Industry. |
| 2003-10 |
Established Fukuoka Office in Hakata-ku, Fukuoka City, built Fukuoka CPC, and began providing Immuno-Cell Therapy Total Support Service to contracted medical institutions. Shares listed on the Tokyo Stock Exchange (Mothers: 2370). |
| 2003-10 |
Established Fukuoka Office in Hakata-ku, Fukuoka-city, constructed Fukuoka CPC, and started providing Immuno-Cell Therapy Total Support Service to contracted Medical Institutions. : MEDINET's shares were listed on Tokyo Stock Exchange (Mothers: 2370) (as of Oct. 8, 2003). |
| 2003-10-08 |
Listed shares on the Tokyo Stock Exchange Mothers Market. |
| 2004-03 |
Obtained ISO9001 certification for the cell medical support business. |
| 2004-03 |
ISO 9001 certification for quality management of cell culturing and processing obtained from the International Organization for Standardization. |
| 2004-05 |
Merged the "Institute of Molecular Immunology" and the "Institute of Molecular Genetics," and renamed the research and development center to the "Institute of Advanced Medical Science." |
| 2004-05 |
Amalgamated the Institute of Molecular Immunology and the Institute of Molecular Genetics, and renamed the Research and Development Center to 'Medinet Medical Institute.' |
| 2004-05 |
Amalgamated the Institute of Molecular Immunology and the Institute of Molecular Genetics, and renamed the Research and Development Center to "Medinet Medical Institute.". |
| 2004-08 |
Launched Japan's first therapeutic cancer tissue storage service, the "Self Cancer Tissue Bank" service. |
| 2004-08 |
Started providing new cancer tissue storage service Self Cancer Cell Depository™. |
| 2007-02 |
Established a cell processing facility (UTokyo 22nd Century Medical Center CPC) within the 22nd Century Medical Center of the University of Tokyo Hospital for the Department of Immuno-Cell Therapy (Immuno-Cell Therapy Division) and launched comprehensive immune cell therapy support services. |
| 2007-02 |
Constructed Tokyo University 22nd Century Medical and Research Center CPC, and started providing Immuno-Cell Therapy Total Support Service to the 'Department of Immunotherapeutics' established inside the 22nd Century Medical and Research Center in the University of Tokyo Hospital. |
| 2007-02 |
Established a cell processing facility (Tokyo University 22nd Century Medical Center CPC) within the 22nd Century Medical Center of the University of Tokyo Hospital for the "Department of Immunocyte Therapy (Immunocyte Therapy Division)" and started comprehensive immune cell therapy support services. |
| 2007-02 |
Constructed Tokyo University 22nd Century Medical and Research Center CPC, and started providing Immuno-Cell Therapy Total Support Service to the "Department of Immunotherapeutics" established inside the 22nd Century Medical and Research Center in the University of Tokyo Hospital. |
| 2007-06 |
Signed a licensing agreement with Osaka Medical Center for Health and Welfare, a National Hospital Organization, to provide technical support for the implementation of immune cell therapy. |
| 2007-06 |
Concluded a license agreement with the National Hospital Organization Osaka Medical Center for immuno-cell therapy technological support at the center. |
| 2007-11 |
Integrated the research and development facility into the Advanced Medical Science Research Institute in Setagaya, Tokyo, and renamed it "Research and Development Center." |
| 2007-11 |
Amalgamated the research and development facility with the Medinet Medical Institute in Setagaya-ku, Tokyo, and renamed it to 'Research and Development Center.' |
| 2007-11 |
Amalgamated the research and development facility with the Medinet Medical Institute in Setagaya-ku, Tokyo, and renamed it to "Research and Development Center.". |
| 2008-01 |
Established Medical Business Management Institute Inc. |
| 2008-01 |
Established Institute of Medical Service Management, Inc. |
| 2011-07 |
Started comprehensive immune cell therapy support services for Kyushu University Center for Advanced Medical Innovation. |
| 2011-07 |
Started Providing Immuno-Cell Therapy Total Support Service to Kyushu University's Center for Advanced Medical Innovation. |
| 2012-04 |
Established a joint research division "Advanced Cell Therapy Research Division" at Kyushu University Center for Advanced Medical Innovation. |
| 2012-04 |
Established the cooperative research department 'Department of Advanced Molecular and Cell Therapy' in Kyushu University Center for Advanced Medical Innovation. |
| 2012-04 |
Established the cooperative research department "Department of Advanced Molecular and Cell Therapy" in Kyushu University Center for Advanced Medical Innovation. |
| 2012-07 |
Entrusted with some operations related to the third-party advanced medical care (high-level medical care) conducted by UTokyo Hospital. |
| 2012-07 |
Started providing its service to the University of Tokyo Hospital which provides autologous γδT lymphocytes in patients with non-small cell lung cancer as advanced medical treatment. |
| 2012-11 |
Started providing NK cell therapy technology. |
| 2013-12 |
Established a subsidiary, MedCell Inc., to work on a new business "Cell Medical Products Business." |
| 2013-12 |
Established a cell culture processing facility for regenerative and cell medicine (Shinagawa CPF) in Shinagawa, Tokyo. |
| 2013-12 |
Established a wholly owned subsidiary 'MEDcell Co., Ltd.', for the Cell Medicinal Product Business. For expansion of the 'Contract Cell Manufacturing Business,' established Cell Processing Facility for regenerative medicine and cell therapy in Shinagawa-ku, Tokyo (Shinagawa CPF). |
| 2013-12 |
Established a subsidiary, Medcell Co., Ltd., to pursue a new business "Cell Medical Products Business": aiming to expand the new business "Cell Processing Business," and set up a cell culture processing facility (Shinagawa CPF) in Shinagawa-ku, Tokyo for regenerative and cell medical use. |
| 2013-12 |
Established a wholly owned subsidiary "MEDcell Co., Ltd.", for the Cell Medicinal Product Business. For expansion of the "Contract Cell Manufacturing Business," established Cell Processing Facility for regenerative medicine and cell therapy in Shinagawa-ku, Tokyo (Shinagawa CPF). |
| 2015-05 |
Obtained manufacturing license for specific cell processed products at Shinagawa CPF. |
| 2015-05 |
Obtained license for the manufacture of specified cell products in Shinagawa CPF. |
| 2016-06 |
Fully relocated research and development functions from Setagaya, Tokyo, to the headquarters. |
| 2016-06 |
Transferred the entire R&D function from Tamagawadai, Setagaya-ku, Tokyo to its Head Office. |
| 2016-10 |
Entrusted with cell processing operations at Ibaraki Prefectural Children's Hospital. |
| 2016-10 |
Contracted cell processing business at Ibaraki Children's Hospital. |
| 2017-05 |
Signed a contract with the General Incorporated Foundation, Health and Medical Science Association, regarding the manufacturing of specific cell processed products. |
| 2017-05 |
Agreement with the Kenkoigaku Association on the manufacture of specified cell products. |
| 2017-10 |
Obtained manufacturing licenses for specific cell processed products at Shin-Yokohama Cell Culture Processing Facility and Osaka Cell Culture Processing Facility. |
| 2017-10 |
Signed a contract with Kowa Central Clinic regarding the manufacturing of specific cell processed products. |
| 2017-10 |
Received regulatory approval to manufacture specified cell products at its Shin-Yokohama Cell Processing Center and Osaka Cell Processing Center. |
| 2017-10 |
Agreement with Miwa Central Clinic regarding manufacturing of specified cell products. |
| 2017-12 |
Signed a licensing agreement with Histogenics for self-cultured cartilage "NeoCart®." |
| 2017-12 |
Entered into license agreement with Histogenics Corporation for Development and Commercialization of NeoCart for the Japanese Market. |
| 2018-03 |
Signed a joint development agreement with the National Hospital Organization to obtain approval for manufacturing and sales of dendritic cell vaccines targeting adult T-cell leukemia as regenerative medicine products. |
| 2018-03 |
Concluded a joint development agreement with the National Hospital Organization with the goal of obtaining approval to manufacture and sell ATL-DC-101, a dendritic cell vaccine for adult T cell leukemia (ATL). |
| 2018-03 |
With the National Hospital Organization concluded a joint development agreement with the goal of obtaining approval to manufacture and sell as a regenerative medicinal product ATL-DC-101, a dendritic cell vaccine for adult T cell leukemia (ATL). |
| 2018-08 |
Integrated Osaka Cell Culture Processing Facility into Shin-Yokohama Cell Culture Processing Facility, and signed absorption merger agreement between subsidiary Medical Business Management Institute Inc. and MedCell Inc. (effective October 1st). |
| 2018-08 |
Integrated Osaka CPC into Shin-Yokohama CPC. |
| 2018-08 |
Conducted an absorption-type merger of two consolidated subsidiaries, Institute of Medical Service Management, Inc. and MEDcell Co., Ltd. The merger took effect on October 1, 2018. |
| 2018-12 |
Signed a contract with JUNTEN BIO Inc. for development of manufacturing technology for regenerative medicine products. |
| 2018-12 |
Signed a contract development agreement with JUNTEN BIO Co.,Ltd. for technology to manufacture regenerative medicinal products. |
| 2019-01 |
Signed a licensing agreement with US BioLegend Inc. |
| 2019-01 |
Concluded a licensing agreement with BioLegend, Inc., headquartered in the US, for the development of research products using one of our novel monoclonal antibodies. |
| 2019-01 |
Concluded a licensing agreement with BioLegend, Inc., which is headquartered in the US, for the development of research products using one of our novel monoclonal antibodies. |
| 2019-04 |
Integrated the Shin-Yokohama Cell Culture Processing Facility into the Shinagawa Cell Culture Processing Facility (Shinagawa CPF). |
| 2019-04 |
Integrated Shin-Yokohama CPC into Shinagawa CPF. |
| 2019-06 |
Relocated headquarters to Heiwajima, Ota-ku, Tokyo. |
| 2019-06 |
Relocated its Head Office to Heiwajima, Ota-ku, Tokyo. |
| 2019-10 |
Signed a licensing agreement for our gamma delta T cell culture processing technology with Taiwan Medigen Biotechnology Corp. |
| 2019-10 |
Entered into a joint research agreement with the National Cancer Center Japan. |
| 2019-10 |
Signed a licensing agreement with Taiwanese listed biopharmaceutical company Medigen Biotechnology Corp. regarding gamma-delta T cell culture technology. |
| 2019-10 |
Signed a joint research agreement with the National Cancer Center. |
| 2019-11 |
Signed a joint research agreement with Kyoto Prefectural University of Medicine and filed a joint patent application. |
| 2019-11 |
Entered into a joint research agreement with Kyushu University. |
| 2019-11 |
Signed a joint research agreement with the Kyoto Prefectural University of Medicine and patent joint application. |
| 2019-11 |
Signed a joint research agreement with National University Corporation Kyushu University. |
| 2020-01 |
Obtained manufacturing license for regenerative medicine products at Shinagawa CPF. |
| 2020-01 |
Obtained license for the manufacture of regenerative medicinal products in Shinagawa CPF. |
| 2022-04 |
Transitioned from the Tokyo Stock Exchange Mothers Market to the Growth Market following a review of market classification. |
| 2022-04 |
Transitioned from Tokyo Stock Exchange Mothers market to Growth market due to the new market classification of the Tokyo Stock Exchange. |
| 2023-02 |
Started providing NKT cell-activating dendritic cell processing technology. |
| 2023-02 |
Started providing processing technology for NKT cell-activated dendritic cells. |
